Sarah Cannon Research Institute Adds Physician Researcher
Sarah Cannon Research Institute (SCRI) has named Anthony A. Meluch, M.D. as a primary investigator.
NASHVILLE, Tenn., May 11, 2005 -- Sarah Cannon Research Institute (SCRI) has named Anthony A. Meluch, M.D. as a primary investigator. A clinical researcher with The Sarah Cannon Cancer Center since 1993, Meluch is also a member of Tennessee Oncology, P.L.L.C.
Dr. Meluch joins SCRI's primary investigator team, directed by F. Anthony Greco, M.D., which also includes John D. Hainsworth, M.D., Howard A. Burris III, M.D., Denise A. Yardley, M.D., David Spigel, M.D. and Suzanne F. Jones, PharmD.
"Dr. Meluch is a thought leader who brings excellent qualifications and experience to our team," said Dr. Greco. "His research interests and passion for advancing patient care will enable us to expand our menu of clinical trials."
Meluch received his undergraduate training at St. Louis University in Missouri, and his medical doctorate from The Ohio State University College of Medicine. He completed an internal medicine residency program and then a fellowship in both hematology and oncology at the University of Alabama in Birmingham; he is board certified in all three subspecialties. His research interests and publications are in malignancies of the upper aerodigestive system, esophagus, head, neck and genitourinary tract.
"Dr. Meluch's vast knowledge and experience as a practicing physician and researcher made him the perfect candidate for this role," said Mark Cianciolo, CEO of Sarah Cannon Research Institute. "His appointment is in line with our goals to expand our team of physician researchers to enhance our ability to develop more clinical trials for more patients."
"I am honored and excited by the opportunity to further my research interests and expand the scope of SCRI's investigations to improve outcomes for people fighting cancer," said Dr. Meluch.
Sarah Cannon Research Institute, a new company created by HCA's MidAmerica Division and Tennessee Oncology, is dedicated to creating and advancing solutions for a healthier tomorrow through clinical research. The institute is the largest community-based research program in the United States, currently conducting clinical trials through a network of more than 600 oncologists in 25 states.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
